Endocrine Abstracts

Background: Metabolic inflexibility in T2DM might result in reliance on free fatty acids (FFA) as substrates to maintain myocardial energy metabolism compared to lean and healthy controls. Thus, we investigated the effects of an acute suppression of circulating FFA on myocardial lipid content and left ventricular function in extreme phenotypes.Methods: T2DM patients (age: 56±11a; BMI: 28±3.5 kg/m2; HbA1c: 7.29±0.88%) and nine he...

Background: Leptin reduces hepatic lipid content in lipodystrophic and overweight, relatively hypoleptinemic NAFLD patients. However, the underlying mechanism is unknown. In rodents, the anti-steatotic action of leptin is mediated by an increase in VLDL secretion and depends on an intact vagal innervation of the liver.Methods: In this randomized, placebo-controlled, crossover trial, we study the effects of a single metreleptin injection (0.1 mg/kg body w...

Objective: Treatment with metreleptin ameliorates hepatic steatosis in patients with lipodystrophy. The anti-steatotic effect of metreleptin is partially independent of its anorexic action, which suggests a direct effect of metreleptin on hepatic lipid metabolism. However, this mechanism is unknown. Based on previous findings in rodents, we hypothesized that metreleptin reduces hepatic lipid content by stimulating very-low density lipoprotein triglyceride (VLDL1-TG) secretion,...